标题
New treatment options for inflammatory bowel diseases
作者
关键词
-
出版物
JOURNAL OF GASTROENTEROLOGY
Volume 53, Issue 5, Pages 585-590
出版商
Springer Nature
发表日期
2018-03-19
DOI
10.1007/s00535-018-1449-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
- (2018) Julián Panés et al. GASTROENTEROLOGY
- Short Duration, Low Intensity, Pooled Fecal Microbiota Transplantation Induces Remission in Patients with Mild-Moderately Active Ulcerative Colitis: A Randomised Controlled Trial
- (2017) Samuel P. Costello et al. GASTROENTEROLOGY
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2017) L.C.S. De Vries et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial
- (2017) Sudarshan Paramsothy et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
- (2016) Yanli Zhuang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease
- (2016) Bram Verstockt et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial
- (2015) Paul Moayyedi et al. GASTROENTEROLOGY
- Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis
- (2015) Noortje G. Rossen et al. GASTROENTEROLOGY
- Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease
- (2015) Severine Vermeire et al. Journal of Crohns & Colitis
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- Review article: anti-adhesion therapies for inflammatory bowel disease
- (2014) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comprehensive Intestinal T Helper Cell Profiling Reveals Specific Accumulation of IFN-γ+IL-17+Coproducing CD4+ T Cells in Active Inflammatory Bowel Disease
- (2014) Anna-Maria Globig et al. INFLAMMATORY BOWEL DISEASES
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease
- (2012) F. Zorzi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
- (2012) Stephan R. Targan et al. GASTROENTEROLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started